Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
Huijuan JiangTint LwinXiaohong ZhaoYuan RenGrace LiLynn MoscinskiBijal ShahJianguo TaoPublished in: British journal of haematology (2018)